Dapoxetine Early 2006 Launch Expectations Premature, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson does not expect FDA approval of its premature ejaculation therapy dapoxetine in time for an early 2006 launch
You may also be interested in...
Dapoxetine Delay: J&J’s Premature Ejaculation Drug “Not Approvable” At FDA
Alza says it will continue the global development program and address FDA’s questions.
Dapoxetine Delay: J&J’s Premature Ejaculation Drug “Not Approvable” At FDA
Alza says it will continue the global development program and address FDA’s questions.
J&J Submits Dapoxetine NDA For Premature Ejaculation
The company is waiting to see if the selective serotonin reuptake inhibitor will receive priority review. Submission is slightly earlier than expected.